Significant progress has been made in the treatment of AML with the development of small molecular inhibitors, such as the FLT3 inhibitor midostaurin, the Bcl-2 inhibitor venetoclax and IDH inhibitors [6–8]. This evidence concerns the gene BCL2 and acute myeloid leukemia.